
|Articles|February 20, 2006
New biologic helps those with PI help themselves
Until now, patients with primary immunodeficiency (PI) were treated with intravenous immunoglobulin (IVIg) infusions, which were inconvenient and associated with serious adverse side effects, such as migraine headaches.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
2
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5




























